logo
Black Diamond Therapeutics_Product
Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies. Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options.

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate ...

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update

By Black Diamond Therapeutics, Inc
Published - Nov 08, 2022, 08:04 AM ET
Last Updated - Mar 25, 2024, 10:21 AM EDT
  • Presented new data at the 34thEORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic mutations while sparing wild type; both MasterKey therapies demonstrate key attributes of next generation small molecule inhibitors
  • On track to provide a clinical update on BDTX-1535 in 2023 and to file an IND for BDTX-4933 in the first half of 2023
  • Strengthened clinical development leadership with appointment of Melanie Morrison as Senior Vice President, Development Operations, who brings over two decades of experience in oncology drug development
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024